Exelixis Receives Reaffirmation of ‘Buy’ Rating from Guggenheim, Continues to Show Strong Financial Performance
On October 12, 2023, Exelixis (NASDAQ:EXEL), a biotechnology company, received a reaffirmation of its "buy" rating from Guggenheim in a ...